State of Alaska Department of Revenue Has $2.20 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

State of Alaska Department of Revenue trimmed its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,112 shares of the company’s stock after selling 168 shares during the period. State of Alaska Department of Revenue’s holdings in Prestige Consumer Healthcare were worth $2,195,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. grew its stake in Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the period. nVerses Capital LLC grew its stake in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank grew its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after acquiring an additional 181 shares during the period. International Assets Investment Management LLC grew its stake in Prestige Consumer Healthcare by 7,112.5% in the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after acquiring an additional 1,138 shares during the period. Finally, GAMMA Investing LLC grew its stake in Prestige Consumer Healthcare by 49.9% in the third quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock valued at $84,000 after acquiring an additional 387 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

PBH opened at $87.29 on Tuesday. Prestige Consumer Healthcare Inc. has a 52-week low of $62.35 and a 52-week high of $88.36. The firm has a market capitalization of $4.31 billion, a PE ratio of 20.44, a PEG ratio of 2.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.10 and a current ratio of 3.68. The business’s 50-day simple moving average is $79.23 and its 200 day simple moving average is $75.51.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PBH has been the topic of a number of research reports. DA Davidson boosted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Finally, Canaccord Genuity Group upped their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and a consensus target price of $92.50.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.